United Therapeutics (NASDAQ:UTHR) Earns “Buy” Rating from Wedbush

Wedbush reissued their buy rating on shares of United Therapeutics (NASDAQ:UTHR) in a research report released on Wednesday, BenzingaRatingsTable reports. The firm currently has a $244.00 price objective on the biotechnology company’s stock, up from their prior price objective of $243.00.

Other equities research analysts have also issued reports about the stock. BidaskClub lowered shares of United Therapeutics from a hold rating to a sell rating in a report on Wednesday, July 15th. ValuEngine lowered shares of United Therapeutics from a sell rating to a strong sell rating in a report on Thursday, July 2nd. HC Wainwright increased their target price on shares of United Therapeutics from $85.00 to $125.00 and gave the stock a neutral rating in a report on Thursday, June 25th. Oppenheimer initiated coverage on shares of United Therapeutics in a report on Wednesday, June 24th. They issued a buy rating and a $155.00 target price on the stock. Finally, Cowen restated a buy rating and set a $145.00 price objective on shares of United Therapeutics in a report on Friday, June 12th. Three research analysts have rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus target price of $138.10.

Shares of NASDAQ UTHR opened at $111.47 on Wednesday. The company’s 50 day simple moving average is $117.48 and its 200 day simple moving average is $106.45. United Therapeutics has a fifty-two week low of $75.58 and a fifty-two week high of $127.79. The firm has a market capitalization of $5.00 billion, a P/E ratio of 11.65 and a beta of 0.86. The company has a debt-to-equity ratio of 0.26, a current ratio of 7.43 and a quick ratio of 8.46.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, July 29th. The biotechnology company reported $2.41 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $2.41. The company had revenue of $362.00 million for the quarter, compared to analyst estimates of $339.97 million. United Therapeutics had a net margin of 30.04% and a return on equity of 14.90%. The business’s revenue for the quarter was down 3.1% compared to the same quarter last year. During the same period last year, the business posted $3.63 earnings per share. Sell-side analysts expect that United Therapeutics will post 10.4 EPS for the current fiscal year.

In related news, Director Judy D. Olian sold 4,510 shares of the firm’s stock in a transaction on Monday, June 8th. The shares were sold at an average price of $124.96, for a total value of $563,569.60. Following the completion of the transaction, the director now owns 3,490 shares of the company’s stock, valued at $436,110.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Tommy G. Thompson sold 3,100 shares of the firm’s stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $112.56, for a total transaction of $348,936.00. Following the completion of the transaction, the director now directly owns 9,050 shares of the company’s stock, valued at approximately $1,018,668. The disclosure for this sale can be found here. In the last ninety days, insiders sold 242,210 shares of company stock valued at $28,840,232. 10.90% of the stock is owned by insiders.

Institutional investors and hedge funds have recently made changes to their positions in the company. CWM LLC grew its position in shares of United Therapeutics by 696.2% in the 2nd quarter. CWM LLC now owns 207 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 181 shares during the period. Altshuler Shaham Ltd bought a new position in shares of United Therapeutics in the 1st quarter valued at about $28,000. Signaturefd LLC grew its position in shares of United Therapeutics by 139.6% in the 2nd quarter. Signaturefd LLC now owns 321 shares of the biotechnology company’s stock valued at $39,000 after acquiring an additional 187 shares during the period. Banque Cantonale Vaudoise bought a new position in shares of United Therapeutics in the 2nd quarter valued at about $69,000. Finally, First Mercantile Trust Co. bought a new position in shares of United Therapeutics in the 1st quarter valued at about $72,000. 97.99% of the stock is owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.

Featured Article: Quiet Period

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.